Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed B-cell non-Hodgkin's lymphoma (NHL) including the following subtypes:~  * B-cell small lymphocytic lymphoma~ * Marginal zone lymphoma (extranodal, nodal, or splenic)~ * Grade 1-3 follicular lymphoma~ * Mantle cell lymphoma~ * Waldenstrom's macroglobulinemia~* Bidimensionally measurable disease by CT scan with ≥ 1 lesion measuring \> 1.5 cm in a single dimension~* Relapsed or refractory disease after prior antineoplastic therapy, meeting 1 of the following criteria:~  * No response to prior treatment~ * Relapsed disease after prior therapy~* Confirmed CD20-positive disease by immunohistochemistry on biopsy specimen~  * Prior transformation allowed provided there is no evidence of aggressive histology on recent biopsy~* No chronic lymphocytic lymphoma with absolute lymphocyte count \> 5,000/mm³~* No CNS involvement~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Absolute neutrophil count ≥ 1,500/mm\^3 (≥ 1,000/mm³ if due to extensive bone marrow involvement with NHL or splenomegaly)~* Absolute lymphocyte count ≤ 5,000/mm³ (except mantle cell lymphoma with a leukemic phase)~* Platelet count ≥ 50,000/mm\^3~* Bilirubin ≤ 2.0 mg/dL~* AST and ALT ≤ 2.5 times upper limit of normal (ULN) (4 times ULN if liver involvement with NHL)~* Creatinine ≤ 2.0 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile male and female patients must use effective contraception during study~* No serious nonmalignant disease~* No active infection~* No peripheral neuropathy ≥ grade 2 within past 14 days~* No myocardial infarction within the past 6 months~* No New York Heart Association class III or IV heart failure~* No uncontrolled angina pectoris~* No severe uncontrolled ventricular arrhythmias~* No EKG evidence of acute ischemia or active conduction system abnormalities~* Any EKG abnormality must be documented as not medically relevant~* No hypersensitivity to bortezomib, boron, or mannitol~* No known anaphylaxis or immunoglobulin E-mediated hypersensitivity to murine proteins or any component of rituximab (including polysorbate 80 and sodium citrate dehydrate)~* No known infection or exposure to HIV~* No serious psychiatric or medical illness that would preclude study participation~* No active hepatitis B infection~* No other primary malignancy requiring active treatment~* More than 4 weeks since prior significant traumatic injury~PRIOR CONCURRENT THERAPY:~* At least 3 weeks since prior and no concurrent radiotherapy~* More than 4 weeks since prior major surgery or open biopsy~  * Other diagnostic surgery allowed~* More than 4 weeks since prior cytotoxic chemotherapy (6 weeks for nitrosoureas)~* At least 3 months since prior unconjugated monoclonal antibody therapy~* At least 10 weeks since prior radioimmunoconjugates or toxin immunoconjugates (e.g., iodine I 131 tositumomab \[Bexxar\] or ibritumomab tiuxetan \[Zevalin\])~* More than 2 weeks since prior investigational agent~* No prior bortezomib~* No concurrent systemic corticosteroid at greater than the equivalent dose of 20 mg/day of prednisone, unless for treatment of allergic reactions to CT scan dye~* No concurrent major surgery~* No other immunosuppressive agents, unless for treatment of allergic reactions to CT scan dye~* No other concurrent antilymphoma agents~* No other concurrent investigational agent~  * Concurrent participation in another nontreatment study allowed if it does not interfere with participation in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).